Therefore, we next sought to use the pan-RTK inhibitory effect of anlotinib to block the adaptive resistance of trametinib and develop a novel combination strategy for KRAS-mutant NSCLC. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.